2021 operating profit from ordinary activities showed very strong growth, reflecting the excellent dynamism of our business in a rapidly growing market

Exceptional growth in annual revenue of +18.4% at comparable exchange rates and scope (+14.9% at constant rates and real scope), driven by remarkable performance in a very buoyant market

Virbac's first steps into the U.S. food producing animal market.

Virbac announces the acquisition of the remaining minority shares of the Centrovet group.

Excellent revenue growth of 21.2% at the end of September at comparable exchange rates and scope (+16.4% at constant rates and real scope), driven by a very solid third-quarter performance again in all areas

Virbac and Jectas Innovators are proud to announce the signature of a collaborative agreement for the development of animal health vaccine(s).

Significant increase in operating profit from ordinary activities for the first half of 2021 due to the sound market performance and dynamism of our business

Virbac announces the acquisition of additional shares in the Centrovet group.

Exceptional increase in revenue in the first half of 2021, with +21.3% at comparable exchange rates and scope (+14% at constant exchange rates and actual scope), driven by very solid performance in all areas and good market dynamics

2021 Outlook

Virbac, today announced the successful completion of its divestment of the production plant located in Magny-en-Vexin to FC France SAS, a subsidiary of Friulchem SpA and Finest SpA. 

As a non-voting advisor, his role will be mainly to support the good governance of our company by strengthening the complementarity of the skills of the board of directors.

Very strong growth in revenue in the first quarter of 2021 at +22.6% at comparable exchange rates and scope (+12.3% at constant rates), driven by very solid performance in all areas